✕
Login
Register
Back to News
Elicio Therapeutics Prices $15M Registered Direct Offering Of 4,380,313 Common Shares, Proceeds To Fund Phase 1 Development Of ELI-002 7P In Metastatic PDAC
Benzinga Newsdesk
www.benzinga.com
Neutral 88.7%
Neg 0%
Neu 88.7%
Pos 0%
Comments
No comments yet. Be the first!
Join the discussion
Login to comment
Login to comment